Free Trial

Avadel Pharmaceuticals (AVDL) Stock Forecast & Price Target

Avadel Pharmaceuticals logo
$15.47
+2.56 (+19.83%)
(As of 10/31/2024 ET)

Avadel Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
7

Based on 7 Wall Street analysts who have issued ratings for Avadel Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for AVDL.

Consensus Price Target

$24.71
59.76% Upside
According to the 7 analysts' twelve-month price targets for Avadel Pharmaceuticals, the average price target is $24.71. The highest price target for AVDL is $30.00, while the lowest price target for AVDL is $21.00. The average price target represents a forecasted upside of 59.76% from the current price of $15.47.
Get the Latest News and Ratings for AVDL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Avadel Pharmaceuticals and its competitors.

Sign Up

AVDL Analyst Ratings Over Time

TypeCurrent Forecast
11/1/23 to 10/31/24
1 Month Ago
10/2/23 to 10/1/24
3 Months Ago
8/3/23 to 8/2/24
1 Year Ago
11/1/22 to 11/1/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$24.71$24.57$24.57$18.14
Forecasted Upside59.76% Upside86.71% Upside50.47% Upside75.80% Upside
Consensus Rating
Buy
Buy
Buy
Buy

AVDL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AVDL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Avadel Pharmaceuticals Stock vs. The Competition

TypeAvadel PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.79
2.50
Consensus RatingBuyModerate BuyHold
Predicted Upside59.76% Upside16,655.99% Upside10.62% Upside
News Sentiment Rating
Positive News

See Recent AVDL News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/31/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00+72.86%
10/31/2024Oppenheimer
3 of 5 stars
 Boost TargetOutperform ➝ Outperform$29.00 ➝ $30.00+87.03%
10/31/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00+70.41%
6/12/2024Rodman & Renshaw
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$27.00+76.82%
5/9/2024Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$22.00 ➝ $23.00+53.13%
3/5/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$18.00 ➝ $23.00+42.59%
2/6/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$21.00+44.33%
5/2/2023LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$14.50 ➝ $16.00+36.40%
4/26/2023Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Dolezal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
11/30/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$6.50 ➝ $11.00+40.31%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 08:50 PM ET.


AVDL Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Avadel Pharmaceuticals is $24.71, with a high forecast of $30.00 and a low forecast of $21.00.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVDL shares.

According to analysts, Avadel Pharmaceuticals's stock has a predicted upside of 59.76% based on their 12-month stock forecasts.

Avadel Pharmaceuticals has been rated by research analysts at HC Wainwright, Needham & Company LLC, and Oppenheimer in the past 90 days.

Analysts like Avadel Pharmaceuticals more than other "medical" companies. The consensus rating for Avadel Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AVDL compares to other companies.


This page (NASDAQ:AVDL) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners